What happened
CTech reports that Israeli startups raised at least $577.5 million across 12 officially announced funding rounds in August, plus an undisclosed strategic investment in cybersecurity startup Above. The outlet says August 2026 was the strongest August for Israeli startup funding since 2022, despite the month traditionally being quieter because of summer holidays. AI security was the dominant theme, with companies targeting risks created by autonomous agents and AI-powered attacks.
CTech reports that Israeli startups raised at least $577.5 million across 12 funding rounds officially announced during August, with a 13th investment announcement involving cybersecurity startup Above that did not disclose an amount. The outlet describes the result as especially notable because August is traditionally one of the quietest months for Israeli technology funding, when much of the industry slows for summer holidays. According to CTech, August 2026 was the strongest August for Israeli startups since 2022. The article is a roundup of funding announcements rather than an independently audited market-wide investment report, so the total depends on CTech’s stated inclusion criteria and the amounts publicly announced by the companies involved.
CTech reports that the largest round was Alice’s $140 million raise at a valuation of between $700 million and $800 million. The company is applying intelligence on malicious online behavior to security for AI models and agents, according to the outlet. Zenity raised $125 million in a Series C, bringing its reported total funding to $185 million, as it expands its work securing autonomous AI agents. Oligo Security and Corma each raised $60 million. CTech says Oligo is focused on runtime security amid faster AI-assisted vulnerability discovery, while Corma is developing a foundation model for defensive cybersecurity. The source does not independently confirm the companies’ technical performance, customer numbers or the valuation basis for Alice.
CTech also lists several smaller or adjacent rounds. Attestable raised $20 million to develop zero-knowledge cryptography for verifying activity inside AI systems, while June AI raised $20 million in pre-seed funding to build agents for software implementation work. Arrakis Security raised $8 million to monitor what autonomous AI systems do after gaining access to enterprise systems. Xpander raised $7.5 million for infrastructure intended to help companies deploy AI agents across models, clouds and workflows. Above received an investment from CrowdStrike, but CTech reports no dollar amount. The article gives no independent assessment of whether these products are in broad commercial use or how they compare with established security controls.
Beyond security, CTech reports that travel fintech Faye raised $50 million in a Series C at an estimated $500 million valuation and plans to use AI to automate insurance claims while expanding globally. QuantHealth raised $45 million in a Series B for AI simulations of clinical trials; the company says its technology has simulated more than 600 trials and is intended to help drugmakers test decisions before enrolling patients or committing large development budgets. Remepy raised $36 million in a Series A as it prepares its AI-driven Hybridopa Parkinson’s treatment for Phase III and expands into rare tumors through a partnership with Merck. CTech reports the company’s claim that the program improved motor and non-motor symptoms in Phase IIa trials, but the source does not provide trial data or independently verify those results.
Source details: calcalistech.com ↗
Why it matters
The funding pattern suggests investors are placing significant value on security, verification and deployment infrastructure as companies move AI systems from experiments into production. CTech reports major rounds for Alice, Zenity, Oligo Security and Corma, alongside smaller investments in Attestable, June AI, Arrakis Security and Xpander. The source does not independently verify the startups’ product performance, customer adoption or projected market size.
The funding concentration matters because it reflects a practical problem created by the expansion of AI: systems that can act with less direct human intervention introduce new questions about access, behavior, monitoring and accountability. CTech reports that investors backed companies securing AI models and agents, defending against AI-powered cyberattacks, monitoring production environments and helping enterprises move from pilots to deployment. These are operational concerns rather than speculative applications. If the startups’ approaches work, they could give organizations additional ways to control systems that can make decisions or take actions after receiving access.
CTech’s account highlights a shift in the security boundary. Traditional security programs often emphasize identifying vulnerabilities before software is deployed or controlling which users can access systems. The companies in the roundup are pursuing other points of control: Oligo focuses on runtime protection, Arrakis on autonomous agent behavior after access, Zenity on agent security, and Attestable on cryptographic verification. Corma is pursuing a defensive cybersecurity model. The source presents these as company strategies and investor bets, not as established evidence that a separate AI-security layer is always necessary or that these products prevent successful attacks.
The amounts also indicate that AI infrastructure and risk management are being funded alongside more visible AI applications. CTech reports investment in Xpander’s cross-model and cross-cloud deployment infrastructure and June AI’s software-implementation agents, framing enterprise implementation as a bottleneck to broader adoption. That combination suggests investors see deployment reliability, oversight and integration as commercial opportunities in their own right. However, the article does not report customer counts, revenue, retention, independent evaluations or documented incidents resolved by any of the funded companies. It therefore supports a conclusion about investment priorities, not about market leadership or product effectiveness.
The broader public significance remains uncertain. More funding for defensive tools could improve the ability of companies and governments to monitor AI systems, verify actions and respond to attacks. It could also create a crowded market in which overlapping products make security programs harder to evaluate. CTech does not report whether the startups’ technologies have been tested against common enterprise environments, independently audited, approved by regulators or shown to reduce harm. Those gaps matter because security claims can be difficult to compare without common tests and disclosed real-world outcomes.
What to watch next
The most important unknowns are whether these companies can convert funding into widely deployed products, whether AI-specific security tools address risks that existing cybersecurity systems cannot, and whether specialized defensive models outperform general-purpose systems in real-world incidents. CTech also reports substantial funding for AI-enabled travel insurance and clinical-trial simulation, but the source does not establish regulatory approval, clinical outcomes or commercial results from those efforts.
The first issue to watch is whether the funded companies move from promising security concepts to measurable deployments. CTech reports that Zenity is accelerating global expansion, Faye plans global growth and Xpander is building for deployment across models, clouds and workflows. The source does not say how many customers use these products, how widely they are available, or when the companies expect their systems to reach broader production use. Evidence such as independently verified customer deployments, disclosed incidents, external evaluations and documented changes in attack or response rates would clarify whether the funding is translating into practical protection.
A second question is whether AI-specific controls provide capabilities that existing cybersecurity tools lack. Oligo’s runtime-security approach, Arrakis’s focus on autonomous behavior and Attestable’s use of zero-knowledge cryptography address different parts of the problem described by CTech. The outlet also reports Corma’s plan to build a defensive cybersecurity foundation model. Meaningful evaluation would require details about the threats tested, false positives, response speed, integration costs and performance against attacks that use AI. None of those comparisons is provided in the source, so claims about a new security layer remain forward-looking.
The healthcare and insurance investments require their own scrutiny. CTech reports that Faye intends to automate insurance claims and that QuantHealth says it has simulated more than 600 clinical trials. Remepy is preparing an AI-driven treatment program for Phase III and has reported improvements in Phase IIa. These developments could affect decisions involving claims, drug development and patient treatment, but the source does not provide regulatory status, clinical-trial results, error rates, human-review requirements or evidence that simulated outcomes predict real-world outcomes. Those details will be important before judging practical or public benefit.
Finally, the funding total should be tracked against later financing, shutdowns, acquisitions and commercial results. CTech’s August snapshot captures disclosed investment, not the long-term health of Israel’s AI sector or the success of any individual company. It also does not establish whether AI security will remain the leading investment theme, whether the reported valuations will hold, or whether the startups can compete internationally. Future reporting should verify the disclosed amounts, identify independent evidence of use and performance, and distinguish completed deployments from company plans.